Ro-3306

SKU: orb1305602

Description

Ro-3306

Research Area

Cell Biology, Epigenetics & Chromatin, Metabolism Research, Signal Transduction

Key Properties

• CAS Number: 872573-93-8
• MW: 351.45
• Purity: 98.66%
• Formula: C₁₈H₁₃N₃OS₂
• SMILES: O=C1N=C(NCc2cccs2)SC1=Cc1ccc2ncccc2c1
• Target: PKA,SGK,CDK,PKC,ERK,Apoptosis
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:1.25 mg/mL (3.56 mM);DMSO:22.73 mg/mL (64.67 mM)

Bioactivity

• Target IC50:
  CDK1-CyclinB1:35 nM (Ki)|SKOV3 cells:16.92 µM|PKCδ:318 nM(Ki)|CDK1-cyclinB1:35 nM (Ki)|CRC16–159 (primary colon tumor) cells:3503 nM|HEY cells:10.15 µM|CRC057 (liver metastasis) cells:2317 nM|CRC247 (liver metastasis) cells:6303 nM|CDK1-CyclinA:110 nM (Ki)|CRC240 (liver metastasis) cells:3312 nM|CDK2-CyclinE:340 nM (Ki)|ERK:1980 nM(Ki)|CDK2-CyclinE:340 nM (Ki)|CDK1:20 nM(Ki)|CRC401 cells (primary rectal tumor):5258 nM|CRC119 (liver metastasis) cells:3268 nM|SGK:497 nM(Ki)
• In Vivo:
  In HCT116, SW480, and HeLa cell lines, treatment with RO-3306 for 20 hours resulted in a complete cell cycle arrest at the G2/M phase. RO-3306 (10 μM) effectively inhibits oocyte maturation. The compound demonstrates inhibition of CDK1/cyclin B1 (Ki: 35 nM), CDK1/cyclin A (Ki: 110 nM), CDK2/cyclin E (Ki: 340 nM), and CDK4/cyclin D (Ki>2000 nM) activities. Additionally, RO-3306 significantly impedes the proliferation of HCT116 and SW480 cells. Compared to non-tumorigenic cells (MCF 10A and MCF 12A), RO-3306 exhibits a stronger pro-apoptotic effect on cancerous cells (HCT116 and SW480).
• In Vitro:
  METHODS: OVCA-429 and OVCAR-3 ovarian cancer cells were treated with Ro 3306 (1-2.5 nM) for 9 days, and cell viability was measured using crystal violet assay. RESULTS: OVCA-429 and OVCAR-3 cells showed low growth rates at high dose concentrations of Ro 3306 for up to 9 days. Treatment with 2.5 µM Ro 3306 reduced the growth rate of OVCA-429 and OVCAR-3 cells by 75.3% and 87.7%, respectively, on day 9. METHODS: Human tumor cell lines HCT116, SW480 and HeLa were treated with Ro 3306 (9 µM) for 20 h. Cell cycle was detected by Flow cytometry. RESULTS: Treatment of proliferating human tumor cells with Ro 3306 for 20 h resulted in complete G2/M cell cycle arrest.
• Cell Research:
  Log phases cells (25,000) are seeed in 96-well plates and incubated in a 37℃ incubator with CO2, After 24 h, different concentrations of RO-3306 are administered to determine the drug concentrations required to achieve a 50% growth inhibition (IC50). MTT (20 μL, 5 mg/mL stock solution in saline) is added to each well and the cells are incubated for 4 h. Supernatants are removed and formazan crystals from viable cells are solubilized with 200 μL anhydrous DMSO. The absorbance is detected with a 550 model microplate reader at the 565 nm wavelength.(Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Apoptosis, Cyclin dependent kinase, CDK, CDK1, ERK, Inhibitor, inhibit, Ro3306, Ro-3306, Ro 3306, PKCδ, PKA, SGK

Compound Identifiers

PubChem CID

136240579